
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics Inc has demonstrated significant progress in its clinical pipeline, particularly with the recent positive topline results from its DELIVER trial, which de-risked the safety profile of its candidate DYNE-251 for Duchenne Muscular Dystrophy, enhancing investor confidence. The company’s FORCE platform effectively addresses the challenges of delivering therapeutics to muscle tissue and the central nervous system, supporting a robust framework for future growth and potential FDA accelerated approvals. Furthermore, the firm's advancing programs and favorable data positions Dyne as an attractive acquisition target, contributing to an increased price target reflecting the elevated probability of success and overall positive sentiment in the market.
Bears say
Dyne Therapeutics Inc faces a negative outlook primarily due to a significant drop in patient numbers for key clinical endpoints, compounding concerns regarding the effectiveness and safety of its flagship therapies, specifically DYNE-101 and DYNE-251. The stock has been trading at a discount relative to competitors, influenced by apprehensions about the timeline and regulatory pathways for its diseases, particularly DM1, amid potential delays and market competition from other therapeutic developments. Additionally, the company's future revenue estimates may be adversely impacted if its clinical candidates fail to achieve necessary regulatory approvals or meet clinical trial endpoints, with innovation in treatment methods potentially threatening the competitiveness of its current offerings.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares